Pharmicell Signs MOU with Gangnam Severance Hospital to Promote Advanced Regenerative Medicine

Pharmicell, a leading company in stem cell therapy, announced on November 18 that it has signed a memorandum of understanding (MOU) with Gangnam Severance Hospital to promote advanced regenerative medicine and conduct joint clinical research.

The agreement was established to strengthen clinical research capabilities in the field of regenerative medicine and to accelerate the development of new therapeutic technologies by leveraging the infrastructure possessed by both institutions.

Under the agreement, the two parties will cooperate in various areas, including: ▲ establishing regenerative medicine infrastructure and jointly developing cell therapies; ▲ training and discovering clinical researchers specializing in advanced regenerative medicine; and ▲ collaborating on stem cell treatments for overseas medical tourism patients.

After the signing ceremony, an informational session was held for the medical and research staff of Gangnam Severance Hospital to discuss the activation of clinical research in advanced regenerative medicine and detailed directions for research support. At this event, Pharmicell introduced its clinical and development infrastructure and technological capabilities, and presented concrete strategies and plans for joint research between the two institutions.

A Pharmicell representative stated, "Collaboration with Gangnam Severance Hospital, a leading medical institution in Korea, will serve as a major opportunity to enhance our competitiveness in advanced regenerative medicine," adding, "Based on the strengths of both parties, we will establish an integrated cooperation model that connects clinical research to actual treatments."

Meanwhile, Pharmicell recently obtained licenses for human cell management and cell processing facilities, expanding its scope from bone marrow- and adipose-derived mesenchymal stem cells to include umbilical cord-derived mesenchymal stem cells. Based on this, the company is upgrading its cell therapy production infrastructure and strengthening its regenerative medicine-based CDMO business.

Pharmicell continues to expand its research collaborations related to stem cell therapy development and advanced regenerative medicine, thereby securing growth momentum to lead the future regenerative medicine market.

Koo Sungwook, Director of Gangnam Severance Hospital, and Kim Hyunsoo, CEO of Pharmicell (right), are signing a memorandum of understanding (MOU) for the promotion of advanced regenerative medicine and joint clinical research. Pharmicell.